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AbStrAct
Objectives: The aim of the multicenter, open-label, post-marketing, observational survey was to assess doctors’ preferences 
in choosing the progestogen component of the combined contraceptive pill (CCP) and factors affecting this choice in daily 
clinical practice as well as non-contraceptive reasons use of CCP containing drospirenone (CCPD) and patients’ tolerance 
and satisfaction with the treatment. 
Material and methods: This multicenter, open-label, post-marketing, survey was performed nation-wide with the partici-
pation of 222 doctors involving and 10,345 patients treated with CCPD. 
The study questionnaire included questions concerning factors affecting the choice of drospirenone as a component of 
CCP and assessing prescription pattern of the drug as well as tolerance and satisfaction with the use of CCPD. 
results: The doctors frequently declared their choice of drospirenone as the progestogen component of CCP. The most 
important factors affecting the choice of drospirenone, declared by doctors, were tolerance level, consistent regulation of 
menstrual cycle and not causing spotting.
CCPD was prescribed to patients with irregular menstrual cycles (62.7%) and painful menstruation (46.8%). 
During follow-up, significantly increased percentage of patients assessed the tolerance of treatment with CCPD as very 
good (52.5% vs 68.0%; p < 0.01) and very satisfied with its use (61.9% vs 77.8%, p < 0.01).
conclusions: 1) Drospirenone is frequently chosen progestogen component in CCP by Polish gynecologists due to its good 
tolerance, consistent regulation of the menstrual cycle and no spotting in patients opinion. 2) CCPD was most frequently 
used in patients with irregular menstrual cycles and painful menstruation. 3) The patients were satisfied with the use CCPD 
and treatment was well tolerated.
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IntrOductIOn
CCP containing 50 µg of ethylene estradiol and pro-
gestin is the method of choice in the regulation of fertil-
ity in adolescents and young women, unless there are 
contraindications [1–3]. CCP, apart from being used in 
contraception, are also used in women with excessive 
levels of androgens in the blood. The most common cause 
of excess androgens of ovarian origin is polycystic ovary 
syndrome (10–15% of women of childbearing age), much 
less frequently the growth of thecal cells (hypotrichosis) or 
a hormonally active ovarian tumor. The adrenal causes of 
androgen excess include non-classical congenital adrenal 
hyperplasia, Cushing’s syndrome or a tumor of the adrenal 
glands [4]. 
Apart from treating the clinical features of hyperan-
drogenism and the contraceptive effect, CCP exerts many 
other beneficial therapeutic effects, such as: regulation of 
menstrual cycles, elimination of symptoms occurring in the 
course of premenstrual syndrome, decrease of menopausal 
symptoms, treatment of dysmenorrhea and endometriosis, 
increasing bone mineral density, reduction in the incidence 
of functional ovarian cysts, decrease in the incidence of 
uterine fibroids, decrease in the incidence of ectopic preg-
nancies, decrease in the incidence of mastopathy, decrease 
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in the incidence of breast fibroadenomas, decrease in the 
incidence of chronic cystic changes in the breast, decrease 
in the incidence of ovarian and endometrial cancers [5–7].
The estrogen component of this tablet causes a reduc-
tion in the concentrations of free testosterone and dihy-
drotestosterone, as well as dehydroepiandrostenedione and 
androstenedione in the first month of use, it also increases 
the concentration of SHBG, which further reduces the avail-
ability of free androgens [8].
Progestogenic preparations have different affinities for 
estrogen, androgen, glucocorticoid and mineralocorticoid 
receptors, thus translate into differences in the clinical activ-
ity profile. In the treatment of clinical symptoms of hyper-
androgenism, the influence of progestogens on the activity 
of androgen receptors, i.e., their degree of androgenicity 
of progestogens or their antiandrogenic effect, is of crucial 
importance [9]. Drospirenone is a fourth generation pro-
gestogen and affects the activity of progesterone receptors, 
showing also anti-androgenic and anti-mineralocorticoid 
activity [10, 11]. Thanks to its anti-androgenic and anti-min-
eralocorticoid activity, drospirenone alleviates symptoms 
related to water retention and improves the condition of 
acne-prone skin better than levonogestrel [12]. Drospire-
none has also been shown to be more beneficial than other 
progestogens in women with PCOS and on premenstrual 
dysphoric symptoms compared to placebo [13, 14].
Currently, there are no Polish data on the preferences 
of doctors regarding the choice of CCPD and the factors af-
fecting them. It is also unknown how this treatment affects 
the continuation of therapy and how it is tolerated by the 
patients. Therefore, the aim of the multicenter, open-label, 
post-marketing, observational survey was to assess doctors’ 
preferences in choosing the progestogen component of the 
contraceptive pill and factors affecting this choice in daily 
clinical practice. The second aim of the study was to assess 
non-contraceptive reasons use of CCPD as well as patients’ 
tolerance and satisfaction with the treatment. 
MAterIAl And MethOdS
Two hundred and twenty-two gynecologists participated 
in a nation-wide, multicenter, open-label, post-marketing, 
survey. They interviewed 10,345 patients treated with CCPD. 
The survey did not meet the criteria of a medical experiment 
and thus did not require Bioethics Committee approval.
The inclusion criteria for doctors were specialization 
in gynecology, current license to practice, having in your 
practice an appropriate number of patients who meet the in-
clusion criteria for the study, completing and signing the Ap-
plication Form for the Study and sending it to Europharma. 
The inclusion criteria for outpatients were being 18+ 
years old and the use of CCPD minimum 14 days prior to 
study inclusion.
The exclusion criterion was inability to obtain answers 
to questions contained in the survey. 
The physicians participating had dual roles in the survey. 
They answered to the questions regarding their medical 
practice, filled out questionnaires for a minimum of 40 pa-
tients that fulfilled the inclusion criteria during one visit 
survey resulting from a clinical need of the patient. 
The first part of the questionnaire included demograph-
ic data of the doctors (specialization, work experience, place 
of work) and data on their clinical practice [progestogen 
most often chosen as a component the CCP (chlormadi-
none acetate/cyproterone acetate/desogestrel/drospire-
none/norgestimat/dienogest/gestodene/levonorgestrel), 
trait the progestogen that most influences its choice (antian-
drogenic strength/ tolerance level/ lack of spotting/no effect 
on body mass/consistent regulation of menstrual cycles/ 
/elimination of the symptoms of premenstrual syndrome/ 
/positive action in painful menstruation/ positive effect in 
endometriosis treatment/drug price)].
The second part of the questionnaire was conducted 
in two routine outpatient visits resulting from the needs of 
therapy. The part conducted during the first visit included 
patient demographic data (age, education level, place of 
residence and professional activity, staying in a steady re-
lationship), clinical data (nutritional status, number of preg-
nancies and deliveries, menarche, regularity of menstrual 
cycles, reason for use the CCPD, previously used contracep-
tion, duration of use of current contraception and dose of 
drospirenone). The part conducted during the second visit 
(about three months from the previous visit) included data 
on continuing to use contraception and possible causes of 
discontinuation.
In addition, during both visits, the patients’ opinion 
on tolerance of the CCPD and satisfaction with the treat-
ment used were assessed based on a four point scale (1-dif-
ficult to accept discomfort, 2 — acceptable discomfort, 
3 — good tolerance, 4 — very good tolerance and 1 — the 
lack, 2 — moderate, 3 — good, 4 — very good, respectively). 
Statistical analysis was performed with Statistica 12.0 soft-
ware (TIBCO Software Inc., Palo Alto, CA, USA). Values of vari-
ables were presented as percentages and the mean values 
with standard deviations (SD). The differences between visits 
were compared using the chi2 test and chi2 test for trend. 
The value of p < 0.05 was considered statistically significant.
reSultS
doctors’ therapeutic preferences
The study group of doctors’ characteristics is presented in 
Table 1. Drospirenone was the most frequently progestogen 
included in the CCP chosen by doctors participating in the 
study (60,4%). The most common trait of progestogen that 
most influences its choice indicated by doctors were high 
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tolerance levels (76.1%), consistent regulation of menstrual 
cycle (59.9%) and not causing spotting (57.2%), Table 2.
the characteristics of study patients and 
tolerance as well as satisfaction with use ccPd 
The study group of doctors’ characteristics is presented 
in Table 3.
In 44.1% of patients included in the study, CCPD was 
used also for reasons other than contraception. Most often, 
these reasons were irregular menstrual cycles (62.7%) and 
painful menstruation (46.8%). 16.5% of the observed pa-
tients previously used CCP containing another progestogen, 
most often levonorgestrel (20.2%) — data not shown. The 
most common cause of changes in the pill used were no 
benefit effect on accompanying symptoms (30.3%) — data 
not shown. 41.8% of the observed group used CCPD for 
2-3 months. 98.3% of patients used CCPD at a dose of 3 mg 
(Table 3).
The second visit was implemented on average 70 days 
after first visit. The use of the CCPD was continued by 95.8% 
of the observed patients. Among the 4.2% of patients that 
discontinued its use, the most common reasons were de-
liberate decision not to implement prescription (33.7%), 
deliberate withdrawal of the drug due to discomfort with 
its’ using (23.4%), deciding to terminate treatment under the 
influence of other people (14.9%) and no beneficial effects 
on accompanying symptoms (12.4%).
During follow-up, significantly increased percentage of 
patients assessed the tolerance of treatment with CCPD as 
very good (52.5% vs 68.0%; p < 0.01) and very satisfied with 
its use (61.9% vs 77.8%, p < 0.01). While the percentage of 
patients who would recommend this form of contraception 
to a friend was similar (98.3% vs 99.9%), Table 4. 
During follow-up in the study group, 12 adverse events 
in six patients (0.06% of the observed groups) have been 
reported. One of these adverse events, venous thrombosis 
of the lower extremities, was serious (Tab. 5). 
table 1. Characteristics of the study group of doctors (n = 222)
Professional experience n (%)
2–5 years 3 (1.4)
6–15 years 58 (26.1)
16–20 years 11 (5.0)
> 20 years 150 (67.6)
Workplace n (%)
Public hospital 63 (28.4)
Private hospital 3 (1.4)
Public outpatients clinic 33 (14.9)
Private outpatients clinic 24 (10.8)
Private practice 99 (44.6)
Workplace location n (%)
Village 1 (0.5)
City < 50,000 residents 62 (27.9)
City 50–200,000 residents 61 (27.5)
City > 200,000 residents 98 (44.1)
table 2. Doctors preferences and the factors that determine them
Progestogen chosen as a component the ccP [%] rarely Often the most common
Chlormadinone acetate 47.3 50.9 1.8
Cyproterone acetate 81.5 17.6 0.9
Desogestrel 40.1 53.6 6.3
Drospirenone 2.3 37.4 60.4
Norgestimat 43.2 55.9 0.9
Dienogest 22.1 70.3 7.7
Gestodene 36.5 48.2 15.3
Levonorgestrel 32.0 62.6 5.4
trait the progestogen decides about its choice [%] not important Important Very important 
Antiandrogenic strength 5.0 65.3 29.7
Good tolerance 0.5 23.4 76.1
The lack of spotting 9.0 33.8 57.2
No effect on body mass 3.6 45.0 51.4
Very good regulation of menstrual cycles 7.7 32.4 59.9
Very good elimination of the symptoms of premenstrual syndrome 13.5 45.9 40.5
Very good action in painful menstruation 6.3 43.2 50.5
Very good effect in endometriosis treatment 23.9 60.4 15.8
Drug price 33.8 60.4 5.9
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dIScuSSIOn
More than half of the doctors participating in the study 
indicated drospirenone as the most frequently chosen pro-
gestogen in the CCP. The most frequently indicated features 
of the active substance determining its selection were tol-
erance level, consistent regulation of the menstrual cycles 
and no spotting. The importance of the non-contraceptive 
effects of the CCPD for doctors is confirmed by the fact 
that over 40% of patients included in the study also used 
it for reasons other than contraception. The most common 
reasons were irregular menstrual cycles and painful men-
struation, which is consistent with the features indicated 
as important when choosing a progestogen included in 
the CCP. Moreover, the most common changes in the con-
traceptive use were made due to the lack of a beneficial 
effect on the accompanying symptoms. The progestogen 
most often changed to drospirenone was levonorgestrel. 
While, the results of a randomized study showed that the 
CCPD is more effective at relieving the symptoms of pain-
ful periods than the pill containing chlormadinone [15]. 
It should also be noted that in 2010 in Great Britain, similarly 
to the presented study, in over 40% of women the CCPD was 
used for non-contraceptive reasons [16].
During the follow-up, the use of the CCPD was continued 
by 95.8% of the observed patients. Moreover, the percentage 
of patients assessing the tolerance of the CCPD used as “very 
good” increased significantly. It should be noted that 98.3% of 
study women were treated with pills containing 3 mg drospi-
renone. High tolerance of the drug is also confirmed by the 
fact that adverse events were reported in 0.06% of the studied 
group, just one adverse event was severe. The rate of adverse 
table 3. Characteristics of patients study groups treated with CCPD 
(n = 10.345)
Sociodemographic
Age (years) (mean ± SD) (min–max) 28 ± 7 (18–52)





Professional activity n (%)
Working 6.711 (64.9)
Not working 1.025 (9.9)
Pension 27 (0.3)
Student 2.582 (25.0)
Staying in a solid relationship: 7.216 (69.8)
clinical
nutritional status n (%)
Underweight 717 (6.9)
Normal weight 7.795 (75.4)
Overweight 1.712 (16.5)
Obesity 121 (1.2)




> 2 1.111 (10.7)




> 2 585 (5.7)
Age of menarche n (%)
10–11 years 1.074 (10.4)
12–14 years 8.211 (79.4)
> 14 years 1.060 (10.2)
regularity of menstrual cycles n (%)
Regular 6.763 (65.4)
Irregular 3.527 (34.1)
Secondary amenorrhea 55 (0.5)
Non-contraceptive reason to use the CCPD 5.787 (55.9)




Irregular menstrual cycles 2.858 (62.7)
Premenstrual syndrome 1.180 (25.9)
Painful menstruation 2.131 (46.8)
table 3. Characteristics of patients study groups treated with CCPD 
(n = 10.345) (continued)
Endometriosis 172 (3.8)
Abundant menstruation 43 (0.9)
Acne 28 (0.6)
Other 21 (0.5)
duration of taking the ccPd n (%)
< 1 month 1.617 (15.6)
2–3 months 4.327 (41.8)
4–6 months 1.960 (18.9)
7–12 months 1.250 (12.1)
> 12 months 1.191 (11.5)
drospirenone dose used n (%)
3 mg 10.172 (98.3)
2 mg 173 (1.7)
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(n = 9.909) P
tolerance the ccPd (%)
Difficult to accept discomfort 0.6 0 < 0.05
Acceptable discomfort 3.2 1.1 < 0.05
Good tolerance 43.7 30.9 < 0.01
Very good tolerance 52.5 68.0 < 0.01
Satisfaction with the use of the ccPd (%)
The lack 0.6 0.1 < 0.05
Moderate 2.0 0.4 < 0.05
Good 35.5 21.7 < 0.01
Very good 61.9 77.8 < 0.01
Percentage of patients who would recommend this form of contraception to a friend 98.3 99.9 NS
NS: non-statistical
table 5. Adverse events related to treatment with CCPD
Adverse event n
Intolerance 2
Decline in libido 3




Swelling of the breasts 1
Slight swelling of the ankles 1
Total 12
events was much lower than observed in another study. 
In this study was 1.5%, after subtracting the placebo effect, 
discontinued the use of CCP containing 3 mg drospirenone 
[17]. The differences may be the results of the lower number 
of study women (n = 266) and the indication for the use of 
CCP (moderate facial acne), the duration of the treatment as 
well as nature of the study (a randomized, double — blind, 
controlled placebo vs observational study carried out in the 
conditions of everyday clinical practice). The high tolerance 
treatment with CCPD has also been observed in group young 
adult women with primary dysmenorrhea [18]. 
During the follow-up, the percentage of patients who 
were very satisfied with the use of CCPD increased sig-
nificantly. The percentage of patients recommending this 
form of contraception to a friend has also increased slightly. 
Satisfaction with the use of this contraceptive pill may be 
related not only to its contraceptive efficacy and good toler-
ability, but also, as suggested by the results of a previously 
published study with improvement in well-being at the 
time of application these pills and its deterioration after 
discontinuation [19]. It is also suggested that the use of 
a CCP may improve the quality of life [20].
The conducted study describing the daily clinical prac-
tice of Polish gynecologists in the use of CCP confirms previ-
ous observations on the benefits of using the fourth genera-
tion progestogen – drospirenone as a component of CCP 
[17–20], improves the continuation of contraception and 
positively affects the quality of life of patients. This may be 
an indication for doctors that in the event of low tolerance 
of CCP containing another progestogen, switching to CCPD 
will encourage the patient to continue the therapy. This is 
especially important in the group of patients using CCP for 
other than contraceptive reasons.
The main limitation of the presented study is the lack of 
control group treated with placebo and the lack of compari-
sons with CCP containing other progestogens. However, the 
strengths of the study are study group size and assessment 
of daily clinical practice. 
cOncluSIOnS
Drospirenone is frequently chosen as the progestogen 
component in CCP by Polish gynecologists due to its good 
tolerance, consistent regulation of the menstrual cycle and 
no spotting in patients opinion. 
CCPD was most frequently used in patients with irregu-
lar menstrual cycles and painful menstruation. 
The patients were satisfied with the use CCPD and treat-
ment was well tolerated.
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